Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

FDA approves Argenx's Vyvgart Hytrulo prefilled syringe for self-injection in gMG and CIDP, offering flexible dosing and ...

Based on material, the prefilled syringe market is bifurcated into glass prefilled syringes and plastic prefilled syringes. The glass prefilled syringes segment held a larger market share in 2022.

The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

“We understand patients experience MG and CIDP in different ways, and our prefilled syringe is an important innovation that provides patients with more freedom and flexibility to self-administer ...

The Vyvgart Hytrulo prefilled syringe is approved as a 20- to 30-second subcutaneous injection administered by a patient, caregiver, or health care professional. The approval is based on studies ...

The Food and Drug Administration (FDA) has approved a prefilled syringe formulation of Vyvgart ® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) that allows patients to self-inject the medication.

April 10 (Reuters) - The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's (ARGX.BR), opens new tab blockbuster immune disorder drug ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.